Kornitzer Capital Management Inc Aerie Pharmaceuticals Inc Transaction History

Kornitzer Capital Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 Apr 30, 2020	SELL	$11.84 - $25.52 $1.69 Million - $3.64 Million	-142,800 Closed	0 $0
Q4 2019 Jan 31, 2020	SELL	$17.72 - $25.1 $2.49 Million - $3.53 Million	-140,735 Reduced 49.64%	142,800 $3.45 Million
Q3 2019 Nov 04, 2019	BUY	$18.41 - $28.0 $2.42 Million - $3.69 Million	131,680 Added 86.71%	283,535 $5.45 Million
Q2 2019 Jul 31, 2019	SELL	$28.97 - $48.21 $24,769 - $41,219	-855 Reduced 0.56%	151,855 $4.49 Million
Q1 2019 May 01, 2019	SELL	$36.32 - $49.25 $764,536 - $1.04 Million	-21,050 Reduced 12.11%	152,710 $7.25 Million
Q4 2018 Jan 31, 2019	BUY	$33.0 - $60.04 $306,405 - $557,471	9,285 Added 5.65%	173,760 $6.27 Million
Q3 2018 Nov 13, 2018	BUY	$56.15 - $73.9 $9.24 Million - $12.2 Million	164,475 New	164,475 $10.1 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Kornitzer Capital Management Inc , based on Form 13F filings with the SEC.

Stay updated on Kornitzer Capital Management Inc with notifications on news.